NOVEL DRUG DELIVERY OF NANOPARTICLE-BASED CONTROLLED RELEASE SYSTEM AND THEIR EFFECTS ON TARGETTING CANCER CELLS-REVIEW
Main Article Content
Keywords
Nanoparticle-based drug delivery systems (NDDS), Cancer therapy, Drug delivery efficacy, Therapeutic outcomes, Liposomes, Targeted drug delivery, Clinical translation.
Abstract
Background: Nanoparticle-based drug delivery systems (NDDS) have gained significant attention for their potential to improve cancer therapy outcomes. These systems offer the ability to enhance drug delivery efficacy, improve therapeutic outcomes, and reduce adverse effects, making them a promising approach in cancer treatment.
Objective: This systematic review aims to explore advancements in NDDS from 2007 to 2022, focusing on their role in revolutionizing cancer therapy by enhancing drug delivery efficacy, improving therapeutic outcomes, and minimizing side effects.
Methodology: A comprehensive survey was conducted, analyzing sixty-five articles from reputable sources, including Google Scholar, Critical Reviews in Biotechnology, and various nanomedicine-focused publications. The review covers various types of nanoparticles, such as liposomes, polymer micelles, dendrimers, and inorganic nanoparticles, and their applications in cancer therapy. Result: The review highlights the potential of different nanoparticles in improving cancer therapy. It discusses the use of magnetic and gold nanoparticles in hyperthermia, targeted drug delivery, and gene therapy. The study also emphasizes the importance of understanding nanoparticle properties and their interactions with biological systems to optimize therapeutic outcomes. Conclusion: While significant advancements in NDDS have been made, challenges remain in optimizing nanoparticle design, refining targeting strategies, and facilitating clinical translation. Continued research is essential to fully realize the potential of NDDS in cancer therapy.
References
2. Hudson D, Margaritis AJCrib. Biopolymer nanoparticle production for controlled release of biopharmaceuticals. 2014;34(2):161-79.
3. Bianchera A, Bettini RJEOoDD. Polysaccharide nanoparticles for oral controlled drug delivery: The role of drug–polymer and interpolymer interactions. 2020;17(10):1345-59.
4. Krukemeyer M, Krenn V, Huebner F, Wagner W, Resch RJJNN. History and possible uses of nanomedicine based on nanoparticles and nanotechnological progress. 2015;6(6):336.
5. Wang M, Thanou MJPr. Targeting nanoparticles to cancer. 2010;62(2):90-9.
6. Afzal O, Altamimi AS, Nadeem MS, Alzarea SI, Almalki WH, Tariq A, et al. Nanoparticles in drug delivery: From history to therapeutic applications. 2022;12(24):4494.
7. Jadia R, Scandore C, Rai PJIjon, nanomedicine. Nanoparticles for effective combination therapy of cancer. 2016;1(1).
8. Ravera E, Di Santo S, Bosco R, Arboscello C, Chiarlone RJAc, research e. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain. 2011;23:328-32.
9. Bai X, Smith ZL, Wang Y, Butterworth S, Tirella AJM. Sustained drug release from smart nanoparticles in cancer therapy: a comprehensive review. 2022;13(10):1623.
10. Imran SM, Shao GN, Kim H. https://www. sciencedirect. com/science/article/abs/pii/S092633731500346X. 2016.
11. Sethi M, Sukumar R, Karve S, Werner ME, Wang EC, Moore DT, et al. Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity. 2014;6(4):2321-7.
12. Dash S, Murthy PN, Nath L, Chowdhury PJAPP. Kinetic modeling on drug release from controlled drug delivery systems. 2010;67(3):217-23.
13. Mathiowitz EJ. Encyclopedia of controlled drug delivery. 1999.
14. Bravo SA, Lamas MC, Salomón CJJJPPS. In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices. 2002;5(3):213-9.
15. Singh R, Lillard Jr JWJE, pathology m. Nanoparticle-based targeted drug delivery. 2009;86(3):215-23.
16. Weng J, Tong HH, Chow SFJP. In vitro release study of the polymeric drug nanoparticles: development and validation of a novel method. 2020;12(8):732.
17. Gohel MC, Panchal MK, Jogani VVJAP. Novel mathematical method for quantitative expression of deviation from the Higuchi model. 2000;1:43-8.
18. Dai Y, Xu C, Sun X, Chen XJCSR. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. 2017;46(12):3830-52.
19. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2021;71(3):209-49.
20. Qin S-Y, Cheng Y-J, Lei Q, Zhang A-Q, Zhang X-ZJB. Combinational strategy for high-performance cancer chemotherapy. 2018;171:178-97.
21. Balkwill FR, Capasso M, Hagemann TJJocs. The tumor microenvironment at a glance. 2012;125(23):5591-6.
22. Yang S, Gao HJPr. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. 2017;126:97-108.
23. Zhang S, Lv J, Gao P, Feng Q, Wang H, Cheng YJNL. A pH-responsive phase-transition polymer with high serum stability in cytosolic protein delivery. 2021;21(18):7855-61.
24. Li Y, Song L, Lin J, Ma J, Pan Z, Zhang Y, et al. Programmed nanococktail based on pH-responsive function switch for self-synergistic tumor-targeting therapy. 2017;9(45):39127-42.
25. Feng X, Li D, Han J, Zhuang X, Ding JJMS, C E. Schiff base bond-linked polysaccharide–doxorubicin conjugate for upregulated cancer therapy. 2017;76:1121-8.
26. Lee J, Jenjob R, Davaa E, Yang S-GJJoCR. NIR-responsive ROS generating core and ROS-triggered 5′-Deoxy-5-fluorocytidine releasing shell structured water-swelling microgel for locoregional combination cancer therapy. 2019;305:120-9.
27. Oddone N, Pederzoli F, Duskey JT, De Benedictis CA, Grabrucker AM, Forni F, et al. ROS-responsive “smart” polymeric conjugate: Synthesis, characterization and proof-of-concept study. 2019;570:118655.
28. Luo C, Sun B, Wang C, Zhang X, Chen Y, Chen Q, et al. Self-facilitated ROS-responsive nanoassembly of heterotypic dimer for synergistic chemo-photodynamic therapy. 2019;302:79-89.
29. Lee J-H, Jang J-t, Choi J-s, Moon SH, Noh S-h, Kim J-w, et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. 2011;6(7):418-22.
30. Huang I-P, Sun S-P, Cheng S-H, Lee C-H, Wu C-Y, Yang C-S, et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein–mediated drug resistance. 2011;10(5):761-9.
31. Libo Y, Reza FJJPS. Pharmacokinetic profiles of two tablet formulations of Piroxicam. 1996;85:170-6.
32. Augustine R, Hasan A, Primavera R, Wilson RJ, Thakor AS, Kevadiya BDJMTC. Cellular uptake and retention of nanoparticles: Insights on particle properties and interaction with cellular components. 2020;25:101692.
33. Maeda HJAier. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. 2001;41(1):189-207.
34. Poon W, Zhang X, Nadeau JJCRiO. Nanoparticle drug formulations for cancer diagnosis and treatment. 2014;19(3-4).
35. Raju GSR, Benton L, Pavitra E, Yu JSJCc. Multifunctional nanoparticles: recent progress in cancer therapeutics. 2015;51(68):13248-59.
36. Rezvantalab S, Drude NI, Moraveji MK, Güvener N, Koons EK, Shi Y, et al. PLGA-based nanoparticles in cancer treatment. 2018;9:1260.
37. Gavas S, Quazi S, Karpiński TMJNrl. Nanoparticles for cancer therapy: current progress and challenges. 2021;16(1):173.
38. Xu Z, Liu S, Kang Y, Wang MJN. Glutathione-and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy. 2015;7(13):5859-68.
39. Rivas J, Bañobre-López M, Piñeiro-Redondo Y, Rivas B, López-Quintela MJJoM, Materials M. Magnetic nanoparticles for application in cancer therapy. 2012;324(21):3499-502.
40. Lim Z-ZJ, Li J-EJ, Ng C-T, Yung L-YL, Bay B-HJAPS. Gold nanoparticles in cancer therapy. 2011;32(8):983-90.
41. Zhang J, Li S, An F-F, Liu J, Jin S, Zhang J-C, et al. Self-carried curcumin nanoparticles for in vitro and in vivo cancer therapy with real-time monitoring of drug release. 2015;7(32):13503-10.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Iqra Haider
Faculty of Pharmacy, Hamdard University, Madinat al-Hikmah Hakim Mohammed Said Road Karachi-74600, Pakistan.
Zufi Shad
Faculty of Pharmacy, Hamdard University, Madinat al-Hikmah Hakim Mohammed Said RoadKarachi-74600, Pakistan.
Hadia Naz
Faculty of Pharmacy, Hamdard University, Madinat al-Hikmah Hakim Mohammed Said RoadKarachi-74600, Pakistan.
Uroosa Maqbool
Faculty of Pharmacy, Hamdard University, Madinat al-Hikmah Hakim Mohammed Said RoadKarachi-74600, Pakistan.
Misbah Ali
Faculty of Pharmacy, Hamdard University, Madinat al-Hikmah Hakim Mohammed Said RoadKarachi-74600, Pakistan.
Muntaha Iftikhar
Faculty of Pharmacy, Hamdard University, Madinat al-Hikmah Hakim Mohammed Said RoadKarachi-74600, Pakistan.
Saba
Faculty of Pharmacy, Hamdard University, Madinat al-Hikmah Hakim Mohammed Said RoadKarachi-74600, Pakistan.
Aleeza Rubab
Faculty of Pharmacy, Hamdard University, Madinat al-Hikmah Hakim Mohammed Said RoadKarachi-74600, Pakistan.